Clinical Characteristics of Angioedema With Eosinophilia

Hyo-Jung Cho,1 Hye-Soo Yoo,1 Mi-Ae Kim,1 Yoo-Seob Shin,1 Young-Min Ye,1 Dong-Ho Nahm,1 Joo-Hee Kim,2 Jeong-Hee Choi,2 Sun-young Park,1 Hae-Sim Park1*

1Department of Allergy & Clinical Immunology, Ajou University School of Medicine, Suwon, Korea
2Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea
3Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Dongtan, Korea

INTRODUCTION

Angioedema with eosinophilia (AE) is a very rare allergy disease, case reports of which have been published sporadically since 1984. Here, we retrospectively analyzed the clinical features of 10 AE patients in Korea. Nine of the 10 subjects were young females, ranging from 23 to 38 years old. Twenty percent of the subjects had episodic-type AE with high serum IgM and eosinophil counts, while 80% were non-episodic type with normal serum IgM levels but high eosinophil counts. All patients had used systemic corticosteroids to control AE. One patient with refractory episodic-type AE was treated with anti-IgE antibody. This is the first study to evaluate the clinical characteristics of AE in a Korean population.

Key Words: Angioedema; eosinophilia; anti-IgE antibody

MATERIALS AND METHODS

From October 2007 to September 2012, 10 adult patients with AE were analyzed retrospectively from 3 centers (Ajou University Hospital, Hallym University Sacred Heart Hospital Anyang, and Hallym University Sacred Heart Hospital Dongtan) in South Korea. Diagnosis was based on peripheral angioedema on discharge diagnosis. The duration of symptoms and eosinophilia, corticosteroid dose, and HES-organ damage distinguishes it from idiopathic hypereosinophilic syndrome (HES), which may involve internal organs and cause mortality,8 although some consider AE an overlapping syndrome with HES.

In 2012, Nakachi et al. summarized 11 cases of AE treated at a single hospital in Japan and observed the characteristic features and clinical course of AE in Japanese patients.9 In Korea, several case reports of AE have been published sporadically since 1999. Here, we retrospectively analyzed Korean AE patients from 3 University Hospitals and summarized their clinical characteristics and course.

Correspondence to: Hae-Sim Park, MD, PhD, Prof, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, 206 World cup-ro, Yeongtong-gu, Suwon 443-380, Korea.
Tel: +82-31-219-5196; Fax: +82-31-219-5154; E-mail: hspark@ajou.ac.kr
Received: April 3, 2013; Revised: July 8, 2013; Accepted: August 14, 2013

There are no financial or other issues that might lead to conflict of interest.
and treatment outcomes were also noted. Laboratory parameters, including white blood cell (WBC), eosinophil, and WBC differential counts, serum immunoglobulin (IgG, IgA, IgM, and IgE levels), C-reactive protein (CRP) level, and erythrocyte sedimentation rate (ESR), were analyzed. We classified AE into 2 groups, episodic-type (EAE) with more than 2 episodes of AE and non-episodic type (NEAE) with only 1 episode of AE.11

RESULTS

The clinical characteristics of 10 patients diagnosed with AE are summarized in Table 1. Nine of the study subjects were female, and their mean age was 28.5 ± 5.3 (range, 23-38) years at diagnosis. Peripheral edema was observed in distal extremities symmetrically, mostly in the hands and feet without urticaria. Seven patients had a history of allergic disease, such as allergic rhinitis, atopic dermatitis, and bronchial asthma. However, none of these patients had current symptoms, as their underlying allergic diseases were mild and in a state of remission; therefore, we determined that their eosinophilia was not due to underlying allergic disease. No internal organ involvement was documented in any patient. Body weight increase was observed in only one patient (patient 2; 4 kg, 8% of total body weight). All patients had hyper eosinophilia, ranging from 1,000 to 23,400/L. The mean total IgM level was 228.9 mg/dL (reference range, 40-260 mg/dL), ranging from 114 to 391 mg/dL. Most patients showed normal ESR and CRP level except patient 5, who showed an elevated ESR of 52.4 mm/h.

Two (20%) of the study subjects had recurrent episodes of AE and were classified as episodic type (EAE). These 2 patients were young females who tended to have higher levels of serum IgM compared to the patients with non-episodic type (NEAE; 344.0 mg/dL vs. 228.9 mg/dL). Systemic steroids were administered to control their symptoms. The angioedema and eosinophilia in patient 2 improved within 3 days, while patient 1 suffered from frequent recurrences of angioedema with elevated peripheral eosinophil counts when tapering the dose of systemic steroid for 3 years. Therefore, to reduce the patient’s steroid requirement, anti-IgE antibody (omalizumab; monthly, 150 mg) was administered for 6 months. Since the beginning of treatment, there was no evidence of recurrence during the 18-month follow-up period after stopping all medications, including the systemic corticosteroid.

Eight (80%) of the patients were NEAE and had experienced only one episode of AE. One patient was male, while the others were female. Six (75%) of the eight patients had history of allergic disease, which was mild and in well-controlled or remission states. All of these patients showed normal serum IgM levels. Four (50%) of the patients with NEAE recovered without systemic steroids, and another 4 (50%) patients required systemic steroids to control their diseases. The decision of steroid use and dosage was determined by responsible allergists. None of these patients experienced an episode of recurrence during the follow-up period (average, 18 months) after recovery.

DISCUSSION

Since Gleich et al. reported the first four cases in 1984, EAE has been characterized by recurrent episodes of angioedema, fever, leukocytosis, eosinophilia, elevated serum IgM, increased body weight, and a benign clinical course lacking internal organ involvement.14 Additional cases have been reported sporadically in Europe and the United States.12,13 In 1998, Chikama et al. reported a non-episodic variant, which was limited to a single attack. The non-episodic variant consisted of a single attack periodically in Europe and the United States. After that report, there has been effort to define the difference(s) between the 2 phenotypes of AE: episodic and non-episodic. In the present study, 20% of AE pa-

Table 1. Characteristics of the study subjects.

| No. | Sex/Age | AE Type | History of underlying disease | TEC (μL) | ECP (μg/L) | Total IgE (IU/mL) | IgM (mg/dL) | CRP (mg/dL) |
|-----|---------|---------|------------------------------|---------|-----------|----------------|------------|------------|
| 1   | F/34    | Episodic| -                            | 8,730   | NA        | 223            | 344        | 6.0/0.4    |
| 2   | F/20    | Episodic| AR, AD                       | 23,400  | >200      | 38             | 391        | 9.0/0.07   |
| 3   | F/53    | Non-episodic| AR                        | 1,000   | NA        | 300            | NA         | 25.0/NP    |
| 4   | F/44    | Non-episodic| AR, BA                   | 4,500   | 56.4      | 1,478          | NA         | 52.4/0.10  |
| 5   | F/37    | Non-episodic| B-viral carrier          | 2,400   | NA        | 2,197          | NA         | 2.0/0.05   |
| 6   | M/36    | Non-episodic| AR, BA                   | 12,200  | >200      | 75             | 152        | 13.0/0.24  |
| 7   | F/35    | Non-episodic| AR                        | 8,500   | >200      | 14             | 199        | 6.0/0.04   |
| 8   | F/32    | Non-episodic| AR                        | 1,840   | 15.1      | 24             | 114        | 10.0/0.08  |
| 9   | F/31    | Non-episodic| AD                        | 10,304  | 13.9      | 37.7           | 173.4      | 1/1.3      |
| 10  | F/27    | Non-episodic| -                         | 7,770   | NA        | 33.9           | NA         | NP/NP      |

AE: angioedema with eosinophilia, AR: allergic rhinitis, AD: atopic dermatitis, BA: bronchial asthma, NA: not available, TEC: total eosinophil count, ECP: eosinophil cationic protein, IgE: immunoglobulin E, IgM: immunoglobulin M, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein.
tients had a history of recurrent attacks and could be classified as EAE. Constitutional symptoms, such as fever or weight gain, were not observed in any of the study subjects. All of the subjects tended to have high serum IgM and eosinophil counts, as compared to those with NEAE. However, the majority of NEAE cases have been reported in Japanese and Korean populations. In Japanese data, most of the AE patients were young females, and usually presented with a single, transient episode of AE without constitutional symptoms such as fever or weight gain. They also tended to have normal immunoglobulin levels, and about 70% of these patients recovered without systemic corticosteroid treatment. In the present study, 80% of the study subjects had NEAE, similar to the Japanese data. The majority of our patients were young females with localized edema in distal extremities without serious constitutional symptoms, including recurrence, fever, significant weight gain, and internal organ involvement. They also showed normal levels of IgM, CRP, and ESR. Similar to our data, among the 10 cases of AE that have been published in Korea, eight (80%) were of non-episodic type. The reason that NEAE is more common in Japanese and Korean cohorts compared to Western populations may be due to racial or ethnic differences. Previous case reports of Korean patients demonstrated that some cases of NEAE presented with a single episode but with constitutional symptoms, such as fever, significant weight gain, and/or mildly elevated serum IgM. These patients also required systemic steroids to control their disease. These findings suggest no clear distinction between episodic and non-episodic types of AE. NEAE may be a milder form of EAE rather than a distinct disease, as suggested by others.

For the treatment of EAE, systemic corticosteroids have been administered widely. However, some cases of EAE suffered from frequent recurrences and steroid dependency, as observed for patient 1 in this study. There have been a few case reports demonstrating successful treatment of steroid-dependent EAE using imatinib (a tyrosine-kinase inhibitor used in the treatment of multiple cancers) and intravenous immunoglobulin. In the present study, patient 1 was treated with anti-IgE antibody. Previous cases of chronic eosinophilic pneumonia and chronic urticaria treated with anti-IgE therapy were reported. Anti-IgE therapy results in the rapid reduction of free IgE levels and the down-regulation of Fe(R) on basophils, mast cells, and other inflammatory cells. Moreover, anti-IgE therapy exerts profound and significant reductions in airway and tissue eosinophilia in patients with mild allergic asthma and on allergen-induced seasonal increases in circulating and tissue eosinophils in subjects with allergic rhinitis. These findings suggest that anti-IgE therapy can be considered a steroid-sparing option for EAE. One report has suggested that NEAE may be a self-limiting disease. However, most cases of NEAE are treated with systemic steroids, as it may sometimes progress rapidly and present with severe clinical symptoms. Considering that NEAE can be classified as a less severe form of EAE, and EAE can present like an overlapping syndrome with HES, the appropriate use of systemic steroids is beneficial for patients with EAE who expect rapid relief from their symptoms and to prevent the progression of this disease with careful follow-up.

In conclusion, we are the first to report the clinical characteristics of 10 patients with AE in Korea. Although NEAE was more common, systemic steroids can be used to control symptoms and prevent disease progression.

ACKNOWLEDGMENTS

This study is supported by the National Research Foundation (NRF), a grant from the Korean government (MEST 2013-003341).

ORCID

Hae-Sim Park http://orcid.org/0000-0003-2614-0303

REFERENCES

1. Georgy MS, Pongracic JA. Chapter 22: hereditary and acquired angioedema. Allergy Asthma Proc 2012;33 Suppl 1:S73-6.
2. Carr TF, Saltoun CA. Chapter 21: urticaria and angioedema. Allergy Asthma Proc 2012;33 Suppl 1:S70-2.
3. Marković AS, Janezković M. Increasing incidence of angioedema without urticaria—clinical features. Acta Med Croatia 2011;65:119-27.
4. Gleich GJ, Schroeter AL, Marcoux JP, Sachs ML, O’Connell EJ, Kohler PF. Episodic angioedema associated with eosinophilia. N Engl J Med 1984;310:1621-6.
5. Banerji A, Weller PF, Sheikh J. Cytokine-associated angioedema syndromes including episodic angioedema with eosinophilia (Gleich’s Syndrome). Immunol Allergy Clin North Am 2006;26:769-81.
6. Butterfield JH, Leiferman KM, Abrams J, Silver JE, Bower J, Gonchoroff N, Gleich GJ. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood 1992;79:688-92.
7. Bochner BS, Friedman B, Krishnaswami G, Schleimer RP, Lichtenstein LM, Kroege C. Episodic eosinophilia-myalgia-like syndrome in a patient without L-tryptophan use: association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. J Allergy Clin Immunol 1991;88:239-49.
8. Wechsler ME, Fulkerson PC, Bochner BS, Gauvreau GM, Gleich GJ, Henkel T, Kolbeck R, Mathur SK, Ortega H, Patel J, Prussin C, Renzi P, Rothenberg ME, Roufosse F, Simon D, Simon HU, Wardlaw A, Weller PF. Klion AD. Novel targeted therapies for eosinophilic disorders. J Allergy Clin Immunol 2012;130:563-71.
9. Klion AD, Bochner BS, Gleich GJ, Nutman TB, Rothenberg ME, Simon HU, Wechsler ME, Weller PF. The Hypereosinophilic Syndromes Working Group. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006;117:1292-302.
10. Nakachi S, Inokuma S. Eleven cases of angioedema with eosinophilia treated in a single hospital in Japan. Allergol Int 2012;61:259-
Angioedema With Eosinophilia

11. Chikama R, Hosokawa M, Miyazawa T, Miura R, Suzuki T, Tagami H. Nonepisodic angioedema associated with eosinophilia: report of 4 cases and review of 33 young female patients reported in Japan. Dermatology 1998;197:321-5.

12. Jang JS, Kim CH, Kim SS, Oh JE, Park YB, Lee JY, Mo EK. A case report of nonepisodic angioedema with eosinophilia in a Korean patient and a review of the Korean literature. Korean J Intern Med 2006;21:275-8.

13. Agard C, Evain S, Ponge T, Prin L, Hamidou M. Gleich’s syndrome: a case report. Rev Med Interne 2010;31:157-9.

14. Morgan SJ, Prince HM, Westerman DA, McCormack C, Glaspole I. Clonal T-helper lymphocytes and elevated IL-5 levels in episodic angioedema and eosinophilia (Gleich’s syndrome). Leuk Lymphoma 2003;44:1623-5.

15. García-Abujeta JL, Martín-Gil D, Martín M, López R, Suárez A, Rodríguez E, Jerez J, López-Hoyos M. Impaired type-1 activity and increased NK cells in Gleich’s syndrome. Allergy 2001;56:1221-5.

16. Shimasaki AK. Five cases of nonepisodic angioedema with eosinophilia. Rinsho Ketsueki 2001;42:639-43.

17. Matsuda M, Fushimi T, Nakamura A, Ikeda S. Nonepisodic angioedema with eosinophilia: a report of two cases and a review of the literature. Clin Rheumatol 2006;25:422-5.

18. Nagashima T, Matsumoto K, Yamamoto R, Iwamoto M, Minota S. Polyarthritis induced by nonepisodic angioedema associated with eosinophilia. Rheumatol Int 2008;28:1065-6.

19. Jung YH, Oh HS, Yoon YJ, Kim KH, Lee YM, Kim YK, Uh ST, Park CS. A case of nonepisodic angioedema associated with eosinophilia. Korean J Asthma Allergy Clin Immunol 2005;25:73-6.

20. Choi JS, Na SY, Park KS, Bae YJ, Kim TB, Moon HB, Cho YS. A case of thrombotic microangiopathy associated with angioedema with eosinophilia. Korean J Asthma Allergy Clin Immunol 2010;30:58-63.

21. Ha KW, Shin DH, Cheong JH, Cheon KM, Kwon NH, Min TH, Cho DS, Lee BJ, Choi DC. A case of eosinophilic cellulitis associated with angioedema and eosinophilia. J Asthma Allergy Clin Immunol 2003;23:826-32.

22. Ko WK, Yun YJ, Park JW, Park JM, Kang HY, Cho SH, Hong CS. A case of angioedema associated with eosinophilia. J Asthma Allergy Clin Immunol 1999;19:504-8.

23. Stockner I, Thaler J, Fichtel G, Egarter-Vigl E, Wallnöfer W, Wiedermann CJ. Non-episodic angioedema associated with eosinophilia following Mycoplasma pneumoniae infection. Clin Rheumatol 2008;27:1573-6.

24. Scranton SE, Wild CA, England RW. Episodic angioedema with eosinophilia: successful treatment with imatinib. Ann Allergy Asthma Immunol 2008;100:172-4.

25. Orson FM. Intravenous immunoglobulin therapy suppresses manifestations of the angioedema with hypereosinophilia syndrome. Am J Med Sci 2003;326:94-7.

26. Shin YS, Jin HJ, Yoo HS, Hwang EK, Nam YH, Ye YM, Park HS. Successful treatment of chronic eosinophilic pneumonia with anti-IgE therapy. J Korean Med Sci 2012;27:1261-4.

27. Nam YH, Kim JH, Jin H, Hwang EK, Shin YS, Ye YM, Park HS. Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy Asthma Immunol Res 2012;4:357-61.

28. Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E, Gustafsson H, Sandström T, Rak S. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002;110:68-71.

29. Borici-Mazi R, Clements-Baker M. Nonepisodic angioedema with eosinophilia. Ann Allergy Asthma Immunol 2011;106:348-9.

30. Nutman TB. Evaluation and differential diagnosis of marked, persistent eosinophilia. Immunol Allergy Clin North Am 2007;27:529-49.

31. González Delgado P, de la Sen Fernández ML, Soriano Gomis V, Pérez Crespo M, Muñoz Ruiz C, Hernández Niveiro E. Cyclical hypereosinophilia with skin manifestations and a clonal T cell population. J Invest Allergol Clin Immunol 2008;18:401-3.